Browse DNAH9

Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton, cilium axoneme.
Domain PF07728 AAA domain (dynein-related subfamily)
PF12774 Hydrolytic ATP binding site of dynein motor region D1
PF12780 P-loop containing dynein motor region D4
PF12781 ATP-binding dynein motor region D5
PF08385 Dynein heavy chain
PF08393 Dynein heavy chain
PF03028 Dynein heavy chain and region D6 of dynein motor
PF12777 Microtubule-binding stalk of dynein motor
Function

Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP.

> Gene Ontology
 
Biological Process GO:0007018 microtubule-based movement
GO:0007283 spermatogenesis
GO:0048232 male gamete generation
Molecular Function GO:0003774 motor activity
GO:0003777 microtubule motor activity
GO:0016887 ATPase activity
Cellular Component GO:0005874 microtubule
GO:0005875 microtubule associated complex
GO:0005929 cilium
GO:0005930 axoneme
GO:0030286 dynein complex
GO:0044441 ciliary part
GO:0097014 ciliary plasm
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DNAH9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DNAH9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DNAH9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1830.745
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3490.703
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0630.936
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3880.355
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2310.887
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5860.772
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.370.71
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5220.705
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5790.72
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3610.637
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.8620.387
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7320.00977
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DNAH9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.4021.40.081
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277325.916.49.50.389
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275925.918.67.30.569
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211752.447.15.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862550-250.58
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131169.245.523.70.408
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382723.718.55.20.763
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221322.715.47.30.689
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16142521.43.61
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DNAH9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DNAH9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DNAH9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DNAH9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DNAH9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DNAH9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDNAH9
Namedynein, axonemal, heavy chain 9
Aliases Dnahc9; KIAA0357; HL20; HL-20; DYH9; DNAH17L; dynein, axonemal, heavy polypeptide 17-like; dynein, axonemal, ......
Chromosomal Location17p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DNAH9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.